Key Highlights

  • Nyrada (ASX:NYR) shares finished the 6 November 2026 session at $0.495, up 11.24%.
  • Four hospitals are activated and screening in the PROTECT-MI Phase IIa trial, with a further four sites expected by the end of November 2026.
  • Cash was $13.72 million at 30 September 2026, and FDA pre-IND feedback raised no major issues.

During the Trading session on 6 November 2026, Nyrada Inc (ASX:NYR) shares finished at $0.495, up 11.24%, while the S&P/ASX 200 fell 0.49% to 9,020.80. Nyrada is a clinical-stage biotechnology company developing transient receptor potential canonical ion channel inhibitors. Its most recent update is its quarterly activities report and Appendix 4C, dated 19 October 2026.

Latest Development: Quarterly Report (19 October 2026)

Nyrada reported that four hospitals had been activated and were screening patients in the PROTECT-MI Phase IIa clinical trial, with three patients dosed. A further four sites are expected to be activated by the end of November 2026, and recruitment is expected to accelerate as the site network expands.

The company said US FDA pre-IND feedback had been received with no major issues raised, supporting an IND submission for Xolatryp in the first half of calendar 2027. Preclinical data showed significant and sustained cardioprotection in a doxorubicin-induced cardiomyopathy study.

Latest Development: Funding and Pipeline

Cash was $13.72 million at 30 September 2026. The company said A$12.0 million, before costs, had been committed under a placement, including $6.875 million received in the quarter and $5.125 million committed by directors subject to Shareholder approval. A securities purchase plan to raise up to a further $2.0 million was planned for October 2026. Design work is progressing on a Phase Ib oncology trial and a preclinical stroke model.

About the Company

Nyrada is a clinical-stage company whose lead program is Xolatryp, a TRPC ion channel inhibitor. Its activities are directed at Clinical Trials and preclinical studies across cardioprotection, oncology and stroke.

Sector Context

Clinical-stage biotechnology companies depend on trial enrolment, regulatory feedback and access to capital, and early-phase trials often take longer than planned. Regulatory pathways in the United States, including the IND process, are key milestones for drug developers.

Risks to Watch

Enrolment in the PROTECT-MI trial depends on activating the additional sites on schedule. The IND submission is planned for 2027 and may be delayed. Clinical trial results are uncertain, and the company will need additional funding to advance its program beyond the current phase.

Catalysts on Watch

Investors will be watching for the activation of the four additional sites by the end of November 2026, further patient dosing, progress toward the IND submission and the planned Phase Ib oncology trial design.